Gene expression profile derived from BRCA mutated ovarian cancers, termed “the BRCAness profile,” was found to correlate with platinum and PARP inhibitor sensitivity and was efficient in predicting platinum sensitivity of non-BRCA mutated ovarian cancers (Konstantinopoulos et al. 2010). The gene discussed is PARP1; the disease is ovarian cancer.